Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

Anne Li                          7/22/2017                              anne2001.li@gmail.com


A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center — using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice — has revealed new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy. In findings published online by Nature, the Dana-Farber/Boston Children's team — led by pediatric oncologist W. Nick Haining, B.M., B.Ch. — reports that deletion of the Ptpn2 gene in tumor cells made them more susceptible to PD-1 checkpoint inhibitors. PD-1 blockade is a drug that "releases the brakes" on immune cells, enabling them to locate and destroy cancer cells.   


See original article at: https://www.sciencedaily.com/releases/2017/07/170719132316.htm


Post a comment